- Details
- Morgan Roupret sits down with Charles Ryan and discusses the quality of life of patients undergoing urinary diversion after radical cystectomy. Dr. Roupret highlights findings in the subject including properties of a well-functioning neobladder, the volume of a neobladder the day after surgery, and how the experience and technique of the operating urologist may factor into the patient’s quality of...
|
- Details
- Brenda Martone discusses the nurse practitioner's role in assessing and managing immune related complications and toxicities associated with checkpoint inhibitors with Alicia Morgans. Brenda notes that immune related reactions may occur months after a single dose of the immune checkpoint inhibitors pembrolizumab, atezolizumab, and durvalumab. Immune-related reactions may include diarrhea and colit...
|
- Details
- FGFR alterations and specifically ones involving the third and the second isotype of the receptor, FGFR3 and FGFR2, are activated and present in between 15 to 20%, possibly higher, of patients with locally advanced and metastatic bladder cancer. We know that these are genetic drivers and the therapeutic targeting of this pathway can lead to responses. Patients should be selected for therapy based...
|
- Details
- Seth Lerner discusses the evidence supporting the integrated treatment approaches to advanced bladder cancer that begins with neoadjuvant chemotherapy (cisplatin-based therapy) followed by cystectomy demonstrates clinical response for patients with Ashish Kamat. Advances in chemotherapy for metastatic disease have prompted trials of systemic therapy in patients with early stage, high-risk disease...
|
- Details
- Petros Grivas, MD Ph.D. and Alicia Morgans discuss the rapidly changing landscape in the treatment of advanced urothelial cancer. Dr. Grivas discusses the era of immunotherapy in advanced bladder cancer and the development of new drugs, new combinations, and biomarkers. Biographies: Petros Grivas, MD, Ph.D. is an Associate Professor and the Clinical Director of the Genitourinary Cancers Program at...
|
- Details
- Wassim Kassouf and Alicia Morgans discuss the role of neoadjuvant chemotherapy in muscle-invasive bladder cancer (MIBC) including the accuracy of clinical staging and treatments. Biographies: Wassim Kassouf, MD, CM, FRCSC, is a Professor in the Division of Urology and Vice-Chair of the Department of Surgery at McGill University. Dr. Kassouf’s clinical practice focuses on bladder, prostate, and ren...
|
- Details
- Despite the fact that most patients do well with a radical cystectomy, the procedure is physiologically challenging and is associated with real morbidity, including hospitalizations, risk of re-operation, long-term sequelae and post-operative mortality. Jason Efstathiou, MD discusses the progress in trimodality therapy with the combination of surgery, chemotherapy, and radiation. Trimodality thera...
|
- Details
- Andrea Necchi and Alicia Morgans discuss the evolution of neoadjuvant treatment for muscle-invasive bladder cancer (MIBC) including the role of immunotherapy and chemotherapy prior to radical surgery. They discuss the PURE-01study which included all-comers regardless of cisplatin eligibility. The early data from PURE-01 with neoadjuvant pembrolizumab demonstrated a 42% pathological complete respon...
|
- Details
- Scott Tagawa discusses his recent research on the use of antibody-drug conjugate (ADC) sacituzumab govitecan in advanced metastatic urothelial carcinoma. The primary endpoint of the study was the objective response rate and the results of the Phase 2 subset were presented at ASCO GU 2019. The responses were seen with reasonable drug tolerance, a manageable and predictable safety profile, and a rel...
|
- Details
- Josh Meeks reviews the SWOG 1806 study protocol with Alicia Morgans. T he SWOG 1806 study , Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer is expected to begin enrollment in May 2019. This phase III trial studies how well chemotherapy and radiation therapy work with or without atezolizumab in treating patients with localized muscle...
|
